UNITED STATES
           SECURITIES AND EXCHANGE COMMISSION

                  Washington, D.C. 20549
                       FORM 10-QSB

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR
     15(d)OF THE SECURITIES AND EXCHANGE ACT OF
     1934 For the Quarter ended September 30, 2002

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d)
     OF THE EXCHANGE ACT
     For the transition period         to
                               ------    ------

       Commission file number -  000-28787

              Micro Laboratories, Inc.
    (Exact name of Registrant as specified
             in its charter)
<TABLE>

                         <c>                           <c>
  NEVADA                                            05-049-4587
 (State or other (Primary Standard Industrial    (I.R.S. Employer
jurisdictions      Classification Code Number)  Identification number)
of incorporation
or organization

                      29 Lakeside Drive,
                   Johnston, Rhode Island               02919
          (Address of principal executive offices)    (Zip Code)
</TABLE>
       Telephone:  (401) 949-3562
   (Registrant's telephone number,
     including area code)

Indicate by check mark whether the Registrant (1)
has filed all reports required to be filed by
Section 13 or 15(d) of the Securities and Exchange
Act of 1934 during the preceding twelve months (or
such shorter period that the Registrant was
required to file such reports), and (2) has been
subject to file such filing requirements for the
past thirty days.

Yes    x      No
    ------       ------
Indicate the number of shares outstanding of each
of the issuer's classes of common stock, as of the
close of the period covered by this report:

    49,957,500 Shares of Common Stock
               (Title of Class)

Transitional Small Business Disclosure Format
    Yes           No    x
       -------       -------

<PAGE>2
             Micro Laboratories, Inc.

PART I:  Financial Information

         ITEM 1 - Financial statements

         ITEM 2 - Management's' discussion and
                    analysis of financial
                    condition and results of
                    operations

         ITEM 3 - Controls and Procedures

PART II:      Other Information

         ITEM 6 - Exhibits and Reports on Form 8-K








<PAGE>3

                  PART I
         Item 1. Financial Statements:

                  Micro Laboratories, Inc.
                (A Development Stage Company)
                        Balance Sheet
                         (Unaudited)

                            ASSETS
<TABLE>
<CAPTION>
                                                                September 30,
                                                                    2002
                                                                ------------

                                                                  <c>
Current assets:
  Cash                                                           $     3,973
  Prepaid expenses                                                     3,000
                                                                  ----------
      Total current assets                                             6,973

Property and equipment, net of accumulated
  depreciation of $35,043                                             18,048

Other assets                                                           1,600
                                                                  ----------
Total assets                                                     $    26,621
                                                                 ===========
             LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
  Accounts payable                                               $   379,492
  Accrued legal settlement                                            65,000
  Loans from related parties                                         767,259
                                                                  ----------
      Total current liabilities                                    1,211,751


 Common stock, $.001 par value,
  50,000,000 shares authorized, 49,957,500
  shares issued and outstanding                                       49,958
 Additional paid in capital                                        1,531,345
 (Deficit) accumulated during
  development stage                                               (2,766,433)
                                                                 -----------
                                                                  (1,185,130)
                                                                  ----------
                                                                 $    26,621
                                                                 ===========
</TABLE>

      See accompanying notes to
       unaudited financial statements.



<PAGE>4
             Micro Laboratories, Inc.
          (A Development Stage Company)
             Statements of Operations
       Three Months and Six Months Ended
          September 30, 2002 and 2001
For the Period From Inception (August 8, 1997)
             to September 30, 2002
                (Unaudited)
<TABLE>
<CAPTION>
                                                                          Period From
                             Three Months Ended      Six Months Ended     Inception To
                                September 30,          September 30,      September 30,
                           2002              2001    2002         2001       2002
                           ----------------------    -----------------    ------------

                         <c>               <c>     <c>           <c>        <c>
 Sales                    $  4,454     $       -    $  4,454     $       -  $     4,454

 Operating expenses:
  Advertising expense            -             -       7,000             -      486,256
  Professional fees         10,550         3,650      18,400         3,650      401,899
  Consulting                     -             -           -             -      692,805
  Research and development       -             -           -             -      256,203
  Investor services              -             -           -             -      174,810
  Depreciation expense       1,881         1,104       3,762         2,984       38,089
  Office expenses            3,181             -       3,305             -       20,330
  Telephone expense          2,126         1,614       3,974         3,659       53,221
  Other expenses             3,957         4,555       8,154        15,681      454,483
                         ---------     ---------   ---------     ---------    ---------
                            21,695        10,923      44,595        25,974    2,578,096
                         ---------     ---------   ---------     ---------    ---------
(Loss) from operations     (17,241)      (10,923)    (40,141)      (25,974)  (2,573,642)

Other income (expense)
  Legal settlement               -             -           -             -      (65,000)
  Loss on sale of asset          -             -           -             -       (8,653)
  Write-off of obsolete
    inventories                  -             -           -             -      (27,572)
  Loss on impairment of assets   -             -           -             -      (98,220)
  Interest income                -             -           -             -        6,654
                         ---------     ---------   ---------     ---------  -----------
                                 -             -           -             -     (192,791)
                         ---------     ---------   ---------     ---------  -----------
Net (loss)               $ (17,241)    $ (10,923)  $ (40,141)    $ (25,974) $(2,766,433)
                         =========     =========   =========     =========  ===========
Per share information:
Basic and diluted (loss)
  per common share       $       -     $       -   $       -     $       -
                         =========     =========   =========     =========
</TABLE>
   See accompanying notes to
  unaudited financial statements.





<PAGE>5

                  Micro Laboratories, Inc.
                (A Development Stage Company)
                  Statements of Cash Flows
        Six Months Ended September 30, 2002 and 2001
        For the Period From Inception (August 8, 1997)
                    to September 30, 2002
                       (Unaudited)
<TABLE>
<CAPTION>
                                                                            Period From
                                                   Six Months Ended         Inception To
                                                     September 30,          September 30,
                                                2002              2001          2002
                                                ----------------------      -------------

                                             <c>                <c>            <c>
Net income (loss)                            $ (40,141)        $ (25,974)    $(2,766,433)
  Adjustments to reconcile net income to net
   cash provided by operating activities:
   Services provided for common stock                -                 -         945,335
   Depreciation and amortization                 3,762             2,984          50,191
   Loss on sale of equipment                         -                 -           8,653
   Asset impairment losses                           -                 -         109,945
Changes in assets and liabilities:
(Increase) decrease in:
   Prepaid expenses                                  -                 -         (20,033)
   Inventory                                         -                 -         (10,007)
   Deposits                                          -                 -          26,440
Increase (decrease) in:
   Accounts payable                             13,304             1,000         379,492
   Accrued legal settlement                          -                 -          65,000
                                            ----------         ---------    ------------
  Total adjustments                             17,066             3,984       1,555,016
                                            ----------         ---------    ------------
  Net cash provided by (used in)
   operating activities                        (23,075)          (21,990)     (1,211,417)

Cash flows from investing activities:
   Acquisition of property & equipment               -                 -         (79,142)
   Acquisition of formulas & trademarks              -                 -         (75,750)
   Proceeds from sale of equipment                   -                 -           9,825
   Loans to related parties                          -            21,990         (27,664)
                                            ----------         ---------    ------------
  Net cash provided by (used in)
   investing activities                              -            21,990        (172,731)

Cash flows from financing activities:
   Common stock sold for cash                        -                 -         593,198
   Loans from related parties                   27,048                 -         794,923
                                            ----------         ---------    ------------
  Net cash provided by (used in)
   financing activities                         27,048                 -       1,388,121
                                            ----------         ---------    ------------
Increase (decrease) in cash                      3,973                 -           3,973



<PAGE>6

Cash and cash equivalents,
 beginning of period                                 -                 -               -
                                            ----------         ---------    ------------
Cash and cash equivalents,
 end of period                             $     3,973         $       -    $      3,973
</TABLE>

      See accompanying notes to
    unaudited financial statements.



<PAGE>7

Micro Laboratories, Inc.
Notes to Unaudited Financial Statements
September 30, 2002

Basis of presentation

The accompanying unaudited financial statements
have been prepared in accordance with generally
accepted accounting principles for interim
financial information and with the instructions
incorporated in Regulation SB of the Securities and
Exchange Commission.  Accordingly, they do not
include all of the information and footnotes
required by generally accepted accounting
principles for complete financial statements. In
the opinion of management, all adjustments
(consisting of normal recurring adjustments and
accruals) considered necessary for a fair
presentation have been included.

The results of operations for the periods presented
are not necessarily indicative of the results to be
expected for the full year. The accompanying
financial statements should be read in conjunction
with the Company's financial statements for the
year ended March 31, 2002 included in the Company's
filing on Form 10-KSB.

Basic loss per share was computed using the
weighted average number of common shares
outstanding.

The Company had an outstanding advance balance due
to related parties of $767,259 September 30, 2002.
The advance increased by $27,048 during the six
months ended September 30, 2002.






ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Trends and Uncertainties. Demand for Micro's
products will be dependent on, among other things,
general economic conditions, which are cyclical in
nature. Inasmuch as a major portion of Micro's
activities is the receipt of revenues from the sale
of its products, Micro's business operations may be
adversely affected by its competitors and prolonged
recessionary periods.

Capital and Source of Liquidity. Micro currently
has no material commitments for capital
expenditures.

For the six months ended September 30, 2002, Micro
did not pursue any investing activities.

For the six months ended September 30, 2001, Micro
made loans to related parties of $21,990 resulting
in net cash provided by investing activities of
$21, 990.

For the six months ended September 30, 2002, Micro
had amounts due to related parties of $27,048
resulting in net cash provided by financing
activities of $27,048.

For the six months ended September 30, 2001, Micro
did not pursue any investing activities.

On a long-term basis, liquidity is dependent on
commencement of operations as discussed above,
receipt of revenues, additional infusions of
capital and debt financing.

Micro believes that additional capital and debt
financing in the short term will allow Micro to
increase its marketing and sales efforts and become
a fully operational corporation thereafter
resulting in increased revenue and greater
liquidity in the long term. However, there can be
no assurance that Micro will be able to obtain
additional equity or debt financing in the future,
if at all.

Results of Operations. Micro is accurately
classified as a development stage corporation and
has conducted startup and development operations
that include:
   - completed photo shoots, created corporation
logos, brochures, sales literature, product labels
and packaging design, UPCs
   - prepared the product line of six items for
distribution roll out



<PAGE>9

   - completed negotiations with three large
distributors to include west coast, mid west, and
New England to represent and sell the Company's
product lines to national chains.

Micro received revenues of $4,454 for the six
months ended September 30, 2002. For the six months
ended September 30, 2002, Micro had a net loss of
$(40,141).   Operating expenses were $44,595 and
consisted of advertising expense of $7,000,
professional fees of $18,400, depreciation expense
of $3,762, office expenses of $3,305, telephone
expense of $3,974 and other expenses of $8,154.

Micro received no revenues for the six months ended
September 30, 2001. For the six months ended
September 30, 2001, Micro had a net loss of
$(25,974).   Operating expenses were $25,974 and
consisted of professional fees of $3,650,
depreciation expense of $2,984, telephone expense
of $3,659 and other expenses of $15,681.

Plan of Operation. Micro is in the development
stage and has not conducted any significant
operations to date or received any material
operating revenues. Micro has experienced problems,
delays, expenses and difficulties sometimes
encountered by an enterprise in Micro's stage of
development, many of which are beyond Micro's
control. These include, but are not limited to,
unanticipated problems relating to additional costs
and expenses that may exceed current estimates,
competition, product development and acceptance;
and lack of distribution channels.

Micro has a working capital deficiency of
$1,189,000 and is arguably delinquent on some of
its obligations.   Micro intends to market its
products and services utilizing cash made available
from the private sale of its securities and
operations.

Micro's management is currently looking for an
acquisition candidate and is of the opinion that
the proceeds of the sales of its securities and
future revenues will not be sufficient to pay its
expenses for the next twelve months. Advances from
its president will be required to continue the
minimal operations of Micro.



<PAGE>10

Item 3. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, under the supervision and with the
participation of our chief executive officer and
chief financial officer, conducted an evaluation of
our "disclosure controls and procedures" (as
defined in Securities Exchange Act of 1934 (the
"Exchange Act") Rules 13a-14(c)) within 90 days of
the filing date of this quarterly report on Form
10QSB (the "Evaluation Date").  Based on their
evaluation, our chief executive officer and chief
financial officer have concluded that as of the
Evaluation Date, our disclosure controls and
procedures are effective to ensure that all
material information required to be filed in this
quarterly report on Form 10QSB has been made known
to them in a timely fashion.

Changes in Internal Controls

There have been no significant changes (including
corrective actions with regard to significant
deficiencies or material weaknesses) in our
internal controls or in other factors that could
significantly affect these controls subsequent to
the Evaluation Date set forth above.







<PAGE>11

                    PART II
               OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS.

    Not applicable.

ITEM 2.  CHANGES IN SECURITIES.

    Not applicable.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

    Not applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF
          SECURITY HOLDERS.

    Not applicable.

ITEM 5.  OTHER INFORMATION.

    Not applicable.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K.

(a)  Exhibit 99 - Certification pursuant to 18 U.S.C.
Section 1350

    (b)  Not applicable.




               SIGNATURE

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.


/s/ Robert Thistle
----------------------------
Robert Thistle, President


November 18, 2002



<PAGE>12

               CERTIFICATIONS

I, Robert Thistle, certify that:

1.   I have reviewed this quarterly report on Form 10QSB of
Micro Laboratories, Inc.

2.   Based on my knowledge, the quarterly report does not
contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements
made, in light of the circumstances under which such
statements were made, not misleading with respect to the
period covered by this quarterly report;

3.   Based on my knowledge, the financial statements, and
other financial information included in this quarterly
report, fairly present, in all material respects, the
financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in
this quarterly report;

4.   The registrant's other certifying officers and I are
responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules
13a-14 and 15d-14) for the registrant and we have:

(a)  designed such disclosure controls and procedures to
ensure that material information relating to the
registrant, including its consolidated subsidiaries, is
made known to us by others within those entities,
particularly during the period in which this quarterly
report is being prepared;

(b)   evaluated the effectiveness of the registrant's
disclosure controls and procedures as of a date within 90
days prior to the filing date of this quarterly report (the
"Evaluation Date"); and

(c)   presented in this quarterly report our conclusions
about the effectiveness of the disclosure controls and
procedures based on our evaluation as of the Evaluation
Date;

5.   The registrant's other certifying officers and I have
disclosed, based on our most recent evaluation, to the
registrant's auditors and the audit committee of the
registrant's board of directors (or persons performing the
equivalent function):

(a)   all significant deficiencies in the design or
operation of internal controls which could adversely affect
the registrant's ability to record, process, summarize and
report financial data and have identified for the
registrant's auditors any material weaknesses in internal
controls; and

<PAGE>13

(b)   any fraud, whether or not material, that involves
management or other employees who have a significant role
in the registrant's internal controls; and

(6)   The registrant's other certifying officers and I have
indicated in this quarterly report whether or not there
were significant changes in internal controls or in other
factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant
deficiencies and material weaknesses.

Date:  November 18, 2002

/s/Robert Thistle
--------------------------
Robert Thistle
Chief Executive Officer
Chief Financial Officer